Humana March 2018 Pharmacy Policy Updates

Click here to view the Humana Pharmacy Policy Updates »

March 2018 Pharmacy Policy Updates

• Policy Name
• Beleodaq® (belinostat)
• Berinert® (human C1 inhibitor)
• Brovana® (arformoterol inhalation solution)
• Buprenorphine Containing Products
• Cabometyx™ (cabozantinib)
• Cialis® (tadalafil)
• Cinryze® (human C1 inhibitor)
• Daklinza™ (daclatasvir)
• Defitelio® (defibrotide sodium)
• Diabetic Test Strips and Meters
• Dupixent® (dupilumab) Injection
• Elitek® (rasburicase)
• Epclusa® (sofosbuvir and velpatasvir)
• Erectile Dysfunction Medications
• Fibrate Products
• Flector Patch® (diclofenac epolamine patch 1.3%)
• Folotyn® (pralatrexate)
• Fortamet® (metformin, extended release tablets)
• Haegarda® (C1 esterase inhibitor, human)
• Harvoni® (ledipasvir/sofosbuvir)
• Herceptin® (trastuzumab)
• IVIG (immune globulin)
• Inhaled Corticosteroids
• Kadcyla® (ado-trastuzumab emtansine)
• Kalbitor® (ecallantide)
• Keytruda® (pembrolizumab)
• Latuda® (lurasidone)
• Long Acting Anticholinergics (Seebri Neohaler, Lonhala Magnair)
• Long-Acting Beta Agonists
• Lucentis® (ranibizumab)
• Lucentis® (ranibizumab)
• Lutathera® (lutetium Lu 177 dotatate)
• Macugen® (pegaptanib octasodium)
• Mavyret™ (glecaprevir/pibrentasvir)
• Naftin® (naftifine)
• Niaspan® (niacin extended-release)
• Olysio® (simeprevir)
• Oral Isotretinoin Products
• Otezla® (apremilast)
• Pennsaid® (diclofenac topical solution)
• Perforomist® (formoterol fumarate)
• Perjeta® (pertuzumab)
• Ruconest® (C1 esterase inhibitor [recombinant])
• Short Acting Beta Agonist Inhalers
• Siliq™ (brodalumab) Injection
• Sinuva™ (mometasone furoate) sinus implant
• Sovaldi® (sofosbuvir)
• Sprix® (ketorolac tromethamine) nasal spray
• Stelara® (ustekinumab)
• Sutent® (sunitinib)
• Sylvant® (siltuximab)
• Symdeko (tezacaftor-ivacaftor)
• Tarceva® (erlotinib)
• Targretin® (bexarotene)
• Technivie™ (ombitasvir, paritaprevir, ritonavir)
• Topical Antivirals (Zovirax, Zovirax cream, acyclovir ointment, Denavir cream)
• Topical Antivirals (Zovirax®, acyclovir ointment, Zovirax® cream, Denavir®, Xerese®)
• Topical Doxepin Products (doxepin, Prudoxin, Zonalon®)
• Topical Seborrheic Dermatitis Agents
• Torisel® (temsirolimus)
• Tremfya® (guselkumab)
• Verzenio™ (abemaciclib)
• Viekira® (ombitasvir, paritaprevir, ritonavir, and dasaburvir)
• Visudyne® (verteporfin)
• Voltaren® Gel (diclofenac)
• Vosevi™ (sofosbuvir/velpatasvir/voxilaprevir)
• Welchol® (colesevelam)
• Xopenex HFA® (levalbuterol)
• Zepatier® (elbasvir/grazoprevir)
• Zolinza® (vorinostat)
• Zortress® (everolimus)

Click here to view the Humana Pharmacy Policy Updates »

Policy Alerts monitors Commercial and Medicare medical policies for changes. While Payers typically update medical policies annually, there are many reasons why a Payer might review or update a policy. When reviews occur out of cycle, they may go unnoticed. Policy Alerts keeps you informed of upcoming and unexpected coverage changes affecting your product. Quickly understanding the changes Payers make can help you adjust reimbursement strategies impacting your business.

Policy Alerts continuously monitors Commercial and Medicare Payer coverage information to keep you up-to-date on Payer decisions in real-time. Whenever changes occur, email notifications containing a summary of those changes are delivered to your inbox. Clients can access detailed coverage reports and medical policies on the interactive Dashboard portal. Save time and keep focused on the important Payer medical policy reviews and coverage decisions affecting your product!

Policy Alerts takes a client-focused hands-on approach and works hard to provide our customers with helpful insights and actionable analytics over raw data. We understand what our clients need and we are dedicated to making sure we provide timely, accurate and always up-to-date reports that can be used to implement and support a successful reimbursement strategy.

Health economic and reimbursement information provided by Policy Alerts is gathered from third-party sources and is subject to change without notice as a result of complex and frequently changing laws, regulations, rules and policies. This information is presented for illustrative purposes only and does not constitute reimbursement or legal advice.